Trials / Completed
CompletedNCT00281541
A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study of YM155 in Subjects With Unresectable Stage III or Metastatic (Stage IV) Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (estimated)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.
Detailed description
A phase II, multicenter, open-label study in subjects with unresectable Stage III or metastatic (Stage IV) Melanoma to evaluate the efficacy and safety of YM155
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YM155 |
Timeline
- Start date
- 2005-11-01
- Completion
- 2007-06-01
- First posted
- 2006-01-25
- Last updated
- 2012-06-07
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00281541. Inclusion in this directory is not an endorsement.